Industry News
Biotechnology Industry News

Biogen-Eisai’s potential Aduhelm sequel drug granted speedy review by FDA
Biogen-Eisai's potential Aduhelm sequel drug granted speedy review by FDA aarmstrong Mon, 12/27/2021 - 10:56
Editor’s Corner: Fierce Biotech’s top 10 most read stories in 2021
Editor's Corner: Fierce Biotech's top 10 most read stories in 2021 aarmstrong Wed, 12/22/2021 - 09:04
Novartis inks $800M upfront buyout of Gyroscope to continue eye disease gene therapy M&A spree
Novartis inks $800M upfront buyout of Gyroscope to continue eye disease gene therapy M&A spree ntaylor Wed, 12/22/2021 - 03:29
Aiming to make 70 the new 50, Korify rolls out $100M longevity and mental health venture fund
Aiming to make 70 the new 50, Korify rolls out $100M longevity and mental health venture fund ntaylor Wed, 12/22/2021 - 01:50
PhaseBio blames COVID-19 disruption as cardiovascular study axed
PhaseBio blames COVID-19 disruption as cardiovascular study axed aarmstrong Tue, 12/21/2021 - 09:20
Pfizer reports patient death in early-stage Duchenne gene therapy trial, halts enrollment
Pfizer reports patient death in early-stage Duchenne gene therapy trial, halts enrollment aarmstrong Tue, 12/21/2021 - 08:39
Abandoned by Amgen, Cytokinetics lands deal for Chinese rights to heart failure prospect
Abandoned by Amgen, Cytokinetics lands deal for Chinese rights to heart failure prospect ntaylor Tue, 12/21/2021 - 07:51
Abandoned by Amgen, Cytokinetics lands $50M upfront deal for Chinese rights to heart failure prospect
Abandoned by Amgen, Cytokinetics lands $50M upfront deal for Chinese rights to heart failure prospect ntaylor Tue, 12/21/2021 - 07:51
Sanofi gambles $1B upfront on preclinical oncology biotech, bagging Amunix for its pipeline of T-cell engagers
Sanofi gambles $1B upfront on preclinical oncology biotech, bagging Amunix for its pipeline of T-cell engagers ntaylor Tue, 12/21/2021 - 07:17
Chutes & Ladders—CRISPR Therapeutics bids adieu to R&D head in securities filing
Chutes & Ladders—CRISPR Therapeutics bids adieu to R&D head in securities filing fkansteiner Tue, 12/21/2021 - 07:03
The Alzheimer’s debate may not seem positive, but AC Immune’s CEO promises it’s been a breakthrough year
The Alzheimer's debate may not seem positive, but AC Immune's CEO promises it's been a breakthrough year aarmstrong Mon, 12/20/2021 - 19:53
2022 forecast: We wish we had better news for biotech dealmaking, but omicron is coming anyway
2022 forecast: We wish we had better news for biotech dealmaking, but omicron is coming anyway aarmstrong Mon, 12/20/2021 - 15:15
No data, no problem. Senti will go public in $296M SPAC deal before hitting the clinic
No data, no problem. Senti will go public in $296M SPAC deal before hitting the clinic aarmstrong Mon, 12/20/2021 - 13:06
Aptose finally ditches APTO-253 after 3-year clinical hold, phase 1 dud
Aptose finally ditches APTO-253 after 3-year clinical hold, phase 1 dud aarmstrong Mon, 12/20/2021 - 11:59
This is just the Spark: Roche’s new gene therapy manufacturing center leaves space for growth
This is just the Spark: Roche's new gene therapy manufacturing center leaves space for growth aarmstrong Mon, 12/20/2021 - 10:50
Roche adds to Genentech’s ophthalmology program with $670M in biobucks for Lineage Cell Therapeutics’ asset
Roche adds to Genentech's ophthalmology program with $670M in biobucks for Lineage Cell Therapeutics' asset aarmstrong Mon, 12/20/2021 - 10:12
Novartis brings on first TIGIT drug in massive billion-dollar biobucks deal with BeiGene
Novartis brings on first TIGIT drug in massive billion-dollar biobucks deal with BeiGene aarmstrong Mon, 12/20/2021 - 09:37
Forbion arms biotech to stop sudden cardiac death, leading $35M round to fund phase 2 trial of Armgo’s pipeline-in-a-product
Forbion arms biotech to stop sudden cardiac death, leading $35M round to fund phase 2 trial of Armgo's pipeline-in-a-product ntaylor Mon, 12/20/2021 - 06:11
Novartis suffers shock setback as Xolair successor fails phase 3
Novartis suffers shock setback as Xolair successor fails phase 3 ntaylor Mon, 12/20/2021 - 03:07
2022 forecast: Pharma has the tools. Will clinical trials be less white in next year?
2022 forecast: Pharma has the tools. Will clinical trials be less white in next year? klahucik Fri, 12/17/2021 - 14:00